VPC
CADL icon

Vestal Point Capital’s Candel Therapeutics CADL Stock Holding History

Vestal Point Capital’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.51M Buy
+1,125,000
New +$6.12M 0.15% 74

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

Vestal Point Capital's CADL Position: Q1 2026 in Review

Vestal Point Capital opened a new position in Candel Therapeutics (CADL) in Q1 2026: 1,125,000 shares worth $5.51M. The stake represents 0.15% of the portfolio and ranks #74 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Vestal Point Capital held 1,125,000 shares of Candel Therapeutics worth $5.51M as of Q1 2026.
  • Candel Therapeutics was a new Vestal Point Capital position in Q1 2026.
  • Candel Therapeutics made up 0.15% of Vestal Point Capital's portfolio in Q1 2026, its #74 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.